La vendita allo scoperto per National Research dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di National Research. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

National Research (NASDAQ:NRC) Azioni, Report sulle vendite allo scoperto

National Research

National Rural Utilities Cooperative Finance Corp

NYSE

National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.

National Research Corporation - Common Stock

National Research Corp

NASHVILLE RECORDS INC by Nashville Records, Inc.

Nashville Records Inc

NORCOM INFO TECH AG by NORCOM INFORMATION TECHNOLOGIES AG

NorCom Information Technology GmbH & Co KGaA

NRC Group ASA

WIIM

National Research shares are trading lower after the company reported a year-over-year decrease for its Q2 financial results.

National Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRC#NASDAQ">NRC</a>) reported quarterly earnings of $0.26 per share. This is a 10.34 percent decrease over earnings of $0.29 per share from the same period last year. The company reported $35.02 million in sales this quarter. This is a 3.15 percent decrease over sales of $36.16 million the same period last year.

Earnings

News

National Research Q2 GAAP EPS $0.26 Down From $0.29 YoY, Sales $35.02M Down From $36.16M YoY

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Cassava Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>)</h3>
<ul>
<li>On July 1, Cassava Sciences engaged the U.S. Department of Justice (DOJ) and the U.S. Securities and Exchange Commission (SEC) amid ongoing investigations into the company and two senior employees. The company's stock fell around 46% over the past five days and has a <a href="https://www.benzinga.com/quote/SAVA">52-week low of $8.79</a>.</li>
<li>RSI Value: 14.66</li>
<li>SAVA Price Action: Shares of Cassava Sciences fell 5.2% to close at $10.22 on Friday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://pro.benzinga.com/dashboard">latest Cassava Sciences news</a>.</li>
</ul>
<h3 class="wp-block-heading">Owens &amp; Minor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On June 24, Owens &amp; Minor named Jonathan A. Leon as interim CFO. The company's stock fell around 26% over the past month. It <a href="https://www.benzinga.com/quote/OMI">has a 52-week low</a> of $12.47.</li>
<li>RSI Value: 15.74</li>
<li>OMI Price Action: Shares of Owens &amp; Minor fell 4% to close at $12.59 on Friday.</li>
<li><a href="https://pro.benzinga.com/dashboard">Benzinga Pro's charting tool</a> helped identify the trend in Owens &amp; Minor stock.</li>
</ul>
<h3 class="wp-block-heading">Castle Biosciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSTL#NASDAQ">CSTL</a>)</h3>
<ul>
<li>On July 5, Baird analyst Catherine Ramsey maintained Castle Biosciences with an Outperform and maintained a $34 price target. The company's stock fell around 25% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/CSTL">low of $12.07</a>.</li>
<li>RSI Value: 17.90</li>
<li>CSTL Price Action: Shares of Castle Biosciences fell 18.1% to close at $17.40 on Friday.</li>
<li>Benzinga Pro's signals feature notified of a potential <a href="https://pro.benzinga.com/dashboard">breakout in CSTL's shares</a>.</li>
</ul>
<h3 class="wp-block-heading">National Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRC#NASDAQ">NRC</a>)</h3>
<ul>
<li>On May 7, National Research posted a decline in quarterly sales results. Michael Hays, Chief Executive Officer, commented, &#8220;NRC continues to be strongly positioned for growth in our expanding markets. Our decades of benchmarks and trusted thought leadership afford healthcare insights unavailable to most competitors, while our client service remains unmatched, and we continue to roll out innovative new products and technologies.&#8221; The company's shares lost around 10% over the past month. The company's 52-week low is $21.73.</li>
<li>RSI Value: 19.72</li>
<li>NRC Price Action: Shares of National Research gained 0.2% to close at $22.99 on Friday.</li>
<li>Benzinga Pro's earnings calendar was used to track <a href="https://pro.benzinga.com/dashboard">National Research's upcoming earnings report</a>.</li>
</ul>
<h3 class="wp-block-heading">Pacira Biosciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>)</h3>
<ul>
<li>On July 2, Pacira BioSciences said the FDA approved a generic version of Exparel. The company's shares fell around 25% over the past five days. The company <a href="https://www.benzinga.com/quote/PCRX">has a 52-week low</a> of $20.52.</li>
<li>RSI Value: 21.16</li>
<li>PCRX Price Action: Shares of Pacira Biosciences fell 2.8% to close at $21.06 on Friday.</li>
<li>Insider trades for Pacira Biosciences were monitored <a href="https://pro.benzinga.com/dashboard">using Benzinga Pro</a>.</li>
</ul>
Read More: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39646161/top-3-financial-stocks-youll-regret-missing-in-q3">Top 3 Financial Stocks You&#8217;ll Regret Missing In Q3</a>

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

CSTL

PCRX

SAVA

Top 5 Health Care Stocks That May Explode In July

National Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRC#NASDAQ">NRC</a>) reported quarterly earnings of $0.27 per share. This is a 3.57 percent decrease over earnings of $0.28 per share from the same period last year. The company reported $35.31 million in sales this quarter. This is a 3.18 percent decrease over sales of $36.47 million the same period last year.

National Research Q1 EPS $0.27 Down From $0.28 YoY, Sales $35.31M Down From $36.47M YoY

National Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRC#NASDAQ">NRC</a>) reported quarterly earnings of $0.36 per share. This is a 33.33 percent increase over earnings of $0.27 per share from the same period last year. The company reported $38.00 million in sales this quarter. This is a 0.37 percent decrease over sales of $38.14 million the same period last year.

National Research Q4 EPS $0.36 Up From $0.27 YoY, Sales $38.00M Down From $38.14M YoY

ABNB

AKAM

AKTS

ALSN

ANGI

ATOM

BENF

BFAM

BIIB

BRKR

CART

CHCT

CRSR

CTHR

DDOG

DENN

DNUT

ELMD

ENTG

FELE

GCMG

GDDY

GNSS

GORO

HOOD

HYLN

INCY

INMD

INVH

IOSP

IPGP

KTOS

LCII

LDOS

LOPE

LYFT

MODG

NMTC

NTWK

QDEL

REZI

ROIV

RUSHA

RUSHB

SHOP

SITC

SITM

SMWB

SSNC

STAG

TYGO

UFCS

UPST

USAC

VTGN

Earnings Scheduled For February 13, 2024

National Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRC#NASDAQ">NRC</a>) reported quarterly earnings of $0.32 per share. This is a 3.03 percent decrease over earnings of $0.33 per share from the same period last year. The company reported $37.95 million in sales this quarter. This is a 0.67 percent increase over sales of $37.69 million the same period last year.

National Research Q3 EPS $0.32 Down From $0.33 YoY, Sales $37.95M Up From $37.69M YoY

The special dividend is declared&nbsp;to shareholders of record as of the close of business on Monday, September 18, 2023, and payable on Friday, September 22.&nbsp;2023. &nbsp;

Dividends

National Research Declares Special Dividend Of $1.00 Per Share

National Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRC#NASDAQ">NRC</a>) reported quarterly earnings of $0.29 per share. This is a 12.12 percent decrease over earnings of $0.33 per share from the same period last year. The company reported $36.16 million in sales this quarter. This is a 3.03 percent decrease over sales of $37.29 million the same period last year.

National Research Q2 EPS $0.29 Down From $0.33 YoY, Sales $36.16M Down From $37.29M YoY

National Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRC#NASDAQ">NRC</a>) reported quarterly earnings of $0.28 per share. This is a 17.65 percent decrease over earnings of $0.34 per share from the same period last year. The company reported $36.47 million in sales this quarter. This is a 5.12 percent decrease over sales of $38.44 million the same period last year.

National Research Q1 EPS $0.28 Down From $0.34 YoY, Sales $36.47M Down From $38.44M YoY

ABST

ACST

ADPT

ALYA

ANDE

AYTU

BLIN

BTCY

CETX

CIDM

CNDT

CPSI

DAVA

EGAN

EHAB

EMBC

ENLC

FLNG

GILT

ILPT

ISSC

LTHM

MITQ

MTLS

NMIH

NRDS

OSUR

PCYG

POCI

POWW

PRST

REUN

SAFE

SQNS

TGAN

TRIP

TRTN

UDMY

Earnings Scheduled For February 14, 2023

Amandla MK Trust, 10% Owner at National Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRC#NASDAQ">NRC</a>), reported a large insider sell on November 1, according to a new SEC filing. 
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000070487/000156761922019031//Archives/edgar/data/70487/000156761922019031/0001567619-22-019031-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that Trust sold 62,388 shares of National Research. The total transaction amounted to $2,537,000. 
National Research shares are trading down 6.46% at $37.95 at the time of this writing on Wednesday morning.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
In legal terms, an "insider" refers to any shareholder who owns at least 10% of a company. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Important Transaction Codes</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000070487">Check Out The Full List Of National Research's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

National Research 10% Owner Sold $2.54M In Company Stock

National Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRC#NASDAQ">NRC</a>) reported quarterly earnings of $0.33 per share. This is a 13.16 percent decrease over earnings of $0.38 per share from the same period last year. The company reported $37.69 million in sales this quarter. This is a 0.20 percent decrease over sales of $37.77 million the same period last year.

National Research Q3 EPS $0.33 Down From $0.38 YoY, Sales $37.69M Down From $37.77M YoY

KAMN

KOPN

KTCC

LBTYA

LFUS

LGIH

LODE

MDLZ

MMYT

MPLX

MRCY

MSTR

MTCH

MYGN

NAUT

NBIX

NNBR

OSPN

OXLC

PACK

PARR

PAYC

PEAK

PINC

PSTL

PUMP

QUAD

RGEN

RYAM

SBFG

SIMO

SIRI

SMCI

SMLR

SNCY

SOFI

Sony Group Corporation American Depositary Shares

SONY

SPNE

STNG

TECH

TRTX

TRVG

TSLX

UBER

UNVR

USDP

VOYA

VRAY

Earnings Scheduled For November 1, 2022

Amandla MK Trust, 10% Owner at National Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRC#NASDAQ">NRC</a>), reported a large insider sell on October 24, according to a new SEC filing. 
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000070487/000156761922018729//Archives/edgar/data/70487/000156761922018729/0001567619-22-018729-index.htm">U.S. Securities and Exchange Commission</a> on Monday showed that Trust sold 24,444 shares of National Research. The total transaction amounted to $992,127. 
National Research shares are trading up 0.29% at $40.83 at the time of this writing on Tuesday morning.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
In legal terms, an "insider" refers to any shareholder who owns at least 10% of a company. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes To Focus On</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000070487">Check Out The Full List Of National Research's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Massive Insider Trade At National Research

National Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRC#NASDAQ">NRC</a>) reported quarterly earnings of $0.33 per share. This is a 5.71 percent decrease over earnings of $0.35 per share from the same period last year. The company reported $37.30 million in sales this quarter. This is a 2.40 percent increase over sales of $36.42 million the same period last year.

National Research Q2 EPS $0.33 Down From $0.35 YoY, Sales $37.30M Up From $36.42M YoY

Comments

National Research

Vendite allo scoperto

National Research (NASDAQ:NRC) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO